TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now for a near-term rebound setup. TARS is deeply oversold (RSI_6 19) and trading right on key support (64.03) after a mild pullback, while options positioning is aggressively call-skewed (bullish) and hedge funds are meaningfully increasing exposure. With Wall Street’s newer coverage leaning optimistic (two $100 targets) and no negative news flow this week, the risk/reward favors an impatient entry here rather than waiting for a “perfect” pullback.
Price/levels: Post-market 64.54, sitting just above S1 64.033 (immediate support). Next downside support is S2 61.358; upside resistance begins at Pivot 68.363 then R1 72.693. Momentum: RSI_6 at 19.241 signals extreme oversold conditions, which often precede a reflex bounce. Trend: MACD histogram at -0.94 remains below zero (bearish), but it is “negatively contracting,” implying downside momentum is fading. Moving averages: Converging MAs suggest the selloff may be stabilizing rather than accelerating. Pattern stats provided: Similar candlestick-pattern analysis indicates ~70% odds of a +2.09% move next day and +9.59% next week, supporting a short-term rebound bias from this support zone.
scheduled 2026-02-26 after hours—potential catalyst if revenue momentum continues.
raises the probability of a move toward ~61.36 (S2).
Latest reported quarter: 2025/Q3. Growth: Revenue rose to $118.697M, up 146.68% YoY—strong commercial acceleration. Margins: Gross margin ~93% (slightly down YoY by 0.28%), still extremely high. Bottom line: Net income fell to -$12.585M (down 46.26% YoY) and EPS to -$0.30 (down 50.82% YoY), indicating operating costs/investment are outpacing near-term profitability despite rapid revenue growth.
Recent trend: Ratings skew more bullish recently. Barclays initiated Overweight with a $100 target (2025-12-08) and Mizuho initiated Outperform with a $100 target (2025-11-20), highlighting Xdemvy’s commercial potential and projecting >$2B peak sales. Goldman Sachs remains Neutral and raised its target to $51 from $45 (2025-11-06). Wall Street pros: Strong commercial product thesis (Xdemvy), large peak-sales potential, and improving specialty pharma sentiment. Wall Street cons: Not all analysts agree on upside at current levels (Goldman Neutral with a far lower target), reflecting valuation/execution uncertainty and ongoing losses. Influential/congress trades: No recent congress trading data available; insider trend is reported neutral (no significant activity last month).
